20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....
21:10 , May 9, 2019 |  BioCentury  |  Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
22:45 , Apr 29, 2019 |  BC Extra  |  Financial News

April 29 Quick Takes: Sirnaomics, Codiak, Cortexyme, Milestone, NextCure, Applied Therapeutics, Magenta

Sirnaomics closes $47M series C  RNAi therapeutics company Sirnaomics Inc. (Gaithersburg, Md.) raised $22 million in a series C2 round led by Hong Kong-based CR-CP Life Sciences Fund, closing out its series C round for...
22:01 , Apr 12, 2019 |  BC Extra  |  Financial News

Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ. Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous...
18:17 , Mar 7, 2019 |  BC Innovations  |  Distillery Therapeutics

Blocking tumor-associated macrophage SIGLEC15 for solid tumors

DISEASE CATEGORY: Cancer INDICATION: Colorectal; melanoma; brain cancer; solid tumors Patient sample, cell culture and mouse studies suggest inhibiting SIGLEC15 expressed on tumor-associated macrophages could help treat colorectal cancer, melanoma, glioblastoma and other solid tumors....
23:01 , Mar 4, 2019 |  BC Extra  |  Preclinical News

NextCure's macrophage-based alternative to T cell checkpoint inhibitors

A study led by NextCure co-founder and PD-1 pioneer Lieping Chen has found that blocking SIGLEC15 could boost antitumor T cell responses in immunosuppressive tumor microenvironments. NextCure Inc. (Beltsville, Md.) is testing anti-SIGLEC15 mAb NC318...
03:55 , Dec 14, 2018 |  BC Innovations  |  Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
19:59 , Nov 16, 2018 |  BioCentury  |  Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of BioCentury Innovations , a comprehensive source of developments in translational research with knowledgeable perspectives on the key innovations, trends and opportunities in...
15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million on Nov. 13 in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1...
22:43 , Nov 15, 2018 |  BC Innovations  |  Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade...